Dear Shareholders, I am pleased to report that we have completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, our selective oral TYK2/JAK1 inhibitor for autoimmune diseases. Following the…

Dear Shareholders, You will hopefully have seen the publication, this month, of the full dataset from our Phase 1 clinical trial of SDC-1801 in the British Journal of Clinical Pharmacology…

Dear Shareholders, This month, I have been reflecting on our portfolio structure and the recent activities we have undertaken to maintain a diversified pipeline, such as our CNS programme. I…

Dear Shareholders, One of the pleasures in maintaining a portfolio of development-stage drugs is that news is spread around the various programmes. Recently, a peer-reviewed study was published in the…

Dear Shareholders, Thank you to everyone who joined our recent Investor Meet Company (IMC) session following the announcement of our results for the six months ended 31 December 2025. As…

Dear Shareholders, Following my previous letter at the start of the year, I wanted to provide a further update as we continue to make good progress across the business. Last…

Dear Shareholders, As we begin 2026, I would like to wish all our shareholders, partners and supporters a very Happy New Year. This is the first in what will become…